Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Letters to the Editor
Open Access

Authors’ Reply

Meagan L. Adamsick, Roby P. Bhattacharyya, Meghan E. Sise and on behalf of the coauthors
JASN February 2021, 32 (2) 519-520; DOI: https://doi.org/10.1681/ASN.2020121692
Meagan L. Adamsick
1Division of Pharmacy, Massachusetts General Hospital, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roby P. Bhattacharyya
2Division of Infection Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
3Infectious Disease and Microbiome Program, Broad Institute, Cambridge, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Roby P. Bhattacharyya
Meghan E. Sise
4Nephrology Division, Massachusetts General Hospital, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • View PDF
Loading
  • acute renal failure
  • COVID-19

In their letter, Gevers and colleagues1 highlight concerns that remdesivir and its metabolite, GS-441524, may carry a risk of toxicity to the renal tubular epithelium, and that risks may be more considerable for patients with predialysis CKD. We agree that the potential risks of remdesivir and the concern for nephrotoxicity are likely greater in patients with predialysis CKD who have an eGFR of <30 ml/min per 1.73 m2 compared with patients receiving dialysis.

There have been two important updates in the literature regarding coronavirus disease 2019 since we originally wrote our perspective. First, the Solidarity Trial—an unblinded, randomized trial that assigned 2750 patients to remdesivir—found that remdesivir did not reduce mortality, initiation of ventilation, or hospitalization duration compared with standard of care, which has led many to question the effectiveness of remdesivir.2 Second, three retrospective studies now provide clinical experience of remdesivir use in patients with an eGFR of <30 ml/min per 1.73 m2. Thakare et al.3 reported no cases of worsening kidney function attributed to remdesivir in 46 patients with an eGFR of <30 ml/min per 1.73 m2; 30 of these patients were not on dialysis at baseline. Estiverne et al.4 reported no severe liver-function abnormalities attributed to remdesivir among 18 patients with an eGFR of <30 ml/min per 1.73 m2; among 13 patients who were not on dialysis, multiple patients had improving kidney function on remdesivir, with only one case of worsening kidney function considered likely to be related to remdesivir by the study investigators. Ackley et al.5 found that, among 40 patients receiving remdesivir with an eGFR of <30 ml/min per 1.73 m2, only two patients had a >50% increase in creatinine during treatment with remdesivir, and both patients had alternative explanations for AKI.

Although these new data are reassuring, we reiterate the statement we made in our perspective that “conclusive data on the safety of remdesivir among individuals with eGFR <30 ml/min per 1.73 m2 are lacking.” We also enthusiastically agree, and reiterate, that only through well-designed, randomized, placebo-controlled trials that include patients with an eGFR of <30 ml/min per 1.73 m2 can we truly understand the safety and efficacy of remdesivir in patients with advanced kidney disease. Currently, our hospital’s approach is to consider remdesivir (lyophilized powder formulation) in patients with an eGFR of <30 ml/min per 1.73 m2 who are deemed most likely to benefit (hospitalized within 10 days of symptom onset, requiring supplemental oxygen for pneumonia associated with coronavirus disease 2019, and not yet mechanically ventilated). After discussing risks and benefits with the infectious-diseases and nephrology consult teams, we engage in shared decision making with patients and caregivers, highlighting the lack of trial data in patients with an eGFR of <30 ml/min per 1.73 m2.

Disclosures

M.E. Sise has received research funding from Abbvie, Gilead, Merck, and EMD Serono; has served as a scientific advisory board member for Gilead in the area of viral hepatitis; has consultancy agreements with Bioporto; and has received honoraria from lecturing for the International Society of Hemodialysis–Hemodialysis University. All remaining authors have nothing to disclose.

Funding

None.

Footnotes

  • ↵* The original coauthors are Meagan L. Adamsick, Ronak G. Gandhi, Monique R. Bidell, Ramy H. Elshaboury, Roby P. Bhattacharyya, Arthur Y. Kim, Sagar Nigwekar, Eugene P. Rhee, and Meghan E. Sise.

  • Published online ahead of print. Publication date available at www.jasn.org.

  • See related letter to the editor, “Remdesivir in COVID-19 Patients with Impaired Renal Function,” on pages 518–519, and original perspective article, “Remdesivir in Patients with Acute or Chronic Kidney,” in Vol. 31, Iss. 7, on pages 1384–1386.

  • Copyright © 2021 by the American Society of Nephrology

References

  1. ↵
    1. Gevers S,
    2. Welink J,
    3. van Nieuwkoop C
    : Remdesivir in COVID-19 patients with impaired renal function. J Am Soc Nephrol 32: 518–519, 2021
    OpenUrl
  2. ↵
    1. Pan H,
    2. Peto R,
    3. Henao-Restrepo AM,
    4. Preziosi MP,
    5. Sathiyamoorthy V,
    6. Abdool Karim Q, et al
    .; WHO Solidarity Trial Consortium: Repurposed antiviral drugs for covid-19 - interim WHO solidarity trial results [published online ahead of print December 2, 2020]. N Engl J Med 10.1056/NEJMoa2023184pmid:33264556
    OpenUrlPubMed
  3. ↵
    1. Thakare S,
    2. Gandhi C,
    3. Modi T,
    4. Bose S,
    5. Deb S,
    6. Saxena N, et al
    .: Safety of remdesivir in patients with acute or chronic kidney disease [published online ahead of print October 10, 2020]. Kidney Int Rep 10.1016/j.ekir.2020.10.005pmid:33073066
    OpenUrlPubMed
  4. ↵
    1. Estiverne C,
    2. Strohbehn IA,
    3. Mithani Z,
    4. Hirsch JS,
    5. Wanchoo R,
    6. Goyal PG, et al
    .: Remdesivir in patients with estimated glomerular filtration rate < 30mL/min/1.73m2 or on renal replacement therapy [published online ahead of print November 27, 2020]. Kidney Int Rep 10.1016/j.ekir.2020.11.025pmid:33263094
    OpenUrlPubMed
  5. ↵
    1. Ackley TW,
    2. Mcmanus D,
    3. Topal JE,
    4. Cicali B,
    5. Shah S
    : A valid warning or clinical lore: An evaluation of safety outcomes of remdesivir in patients with impaired renal function from a multicenter matched cohort [published online ahead of print November 23, 2020]. Antimicrob Agents Chemother 10.1128/AAC.02290-20pmid:33229428
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 32 (2)
Journal of the American Society of Nephrology
Vol. 32, Issue 2
February 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Authors’ Reply
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Authors’ Reply
Meagan L. Adamsick, Roby P. Bhattacharyya, Meghan E. Sise, on behalf of the coauthors
JASN Feb 2021, 32 (2) 519-520; DOI: 10.1681/ASN.2020121692

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Authors’ Reply
Meagan L. Adamsick, Roby P. Bhattacharyya, Meghan E. Sise, on behalf of the coauthors
JASN Feb 2021, 32 (2) 519-520; DOI: 10.1681/ASN.2020121692
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Funding
    • Footnotes
    • References
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Clinical Studies of Vaccine Efficacy
  • Authors’ Reply: Clinical Studies of Vaccine Efficacy
  • Calcium-Based Phosphate Binders and Plasma Oxalate Concentration in Dialysis Patients
Show more Letters to the Editor

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • Remdesivir in COVID-19 Patients with Impaired Renal Function
  • Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19
  • Google Scholar

Keywords

  • acute renal failure
  • COVID-19

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals

© 2022 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire